European Journal of Pediatric Surgery 1998-08-01

Cerebral ischemia reperfusion-induced vasogenic brain edema formation in rats: effect of an intracellular histamine receptor antagonist.

L Németh, M A Deli, A Falus, C A Szabó, C S Abrahám

Index: Eur. J. Pediatr. Surg. 8(4) , 216-9, (1998)

Full Text: HTML

Abstract

Resuscitation in pediatric emergency and some neurological interventions may result in ischemia reperfusion-induced cerebral injuries. Histamine is one of the well established mediators of cerebral swelling and H1- and H2-receptor antagonists could prevent the development of ischemic brain edema. In the present study, time-dependent changes in the blood-brain barrier (BBB) permeability were investigated in the cerebral cortex of male Wistar rats 1, 2, 4, 8, and 16 h after the beginning of post-ischemic reperfusion. Cerebral ischemia-reperfusion evoked by the 4-vessel occlusion model resulted in significant (p < 0.05) elevations in BBB permeability for albumin, but not for sodium fluorescein. Pre-treatment with a new intracellular histamine receptor antagonist could not prevent ischemic brain edema formation in that model. We conclude that experimental studies could help us to reveal the therapeutic role of histamine receptor antagonists during ischemic brain edema.


Related Compounds

Related Articles:

Enhancement of antitumour activity of cisplatin by N,N-diethyl-2-[4-(phenylmethyl)phenoxy] ethanamine. HCl in human ovarian cancer cells with intrinsic or acquired resistance to cisplatin.

1997-01-01

[Eur. J. Cancer 33(1) , 122-8, (1997)]

Effect of alpha-FMH and DPPE on colony-forming properties of human peripheral progenitor cells.

2002-07-01

[Curr. Med. Chem. 9(14) , 1349-57, (2002)]

Effects of tesmilifene, a substrate of CYP3A and an inhibitor of P-glycoprotein, on the pharmacokinetics of intravenous and oral docetaxel in rats.

2010-08-01

[J. Pharm. Pharmacol. 62(8) , 1084-8, (2010)]

Effects of N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine on the blood-brain barrier permeability in the rat.

2000-01-03

[Eur. J. Pharmacol. 387(1) , 63-72, (2000)]

Tesmilifene may enhance breast cancer chemotherapy by killing a clone of aggressive, multi-drug resistant cells through its action on the p-glycoprotein pump.

2006-01-01

[Med. Hypotheses 66(4) , 715-31, (2006)]

More Articles...